📊 RLYB Key Takeaways
Is RLYB a Good Investment? Thesis Analysis
Rallybio is an early-stage biotech burning $29.8M annually with only $31.4M cash (approximately 1 year runway) against minimal $858K revenue. While the company boasts a strong balance sheet with no debt and improving loss metrics (net income improved 84.5% YoY), the operating losses of $33.1M vastly exceed revenue generation, indicating pre-commercial or very early-stage drug development with severe execution risk and likely need for dilutive financing within 12 months.
Why Buy RLYB? Key Strengths
- Strong balance sheet with $31.4M cash and zero debt
- Excellent liquidity position (14.50x current and quick ratios)
- Improving net loss trajectory (84.5% YoY improvement in net income)
- Revenue growing 34.9% YoY from early base
RLYB Investment Risks to Consider
- Severe cash burn of $29.8M annually against minimal $858K revenue creates approximately 1-year runway
- Operating losses of $33.1M indicate pre-commercial stage with no clear path to profitability
- Extreme negative operating margin (-3853.6%) suggests significant R&D burn typical of biotech with high execution risk
- Will likely require dilutive equity financing within 12 months to extend runway
- Limited revenue visibility and commercial-stage drug data
Key Metrics to Watch
- Cash balance and quarterly burn rate trajectory
- Clinical trial progress and regulatory milestones for pipeline
- Revenue growth rate and product commercialization timeline
- Operating expense reduction and burn rate efficiency
- Financing announcements and potential dilution impacts
RLYB Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 14.50x current ratio provides a solid financial cushion.
RLYB Profitability Ratios
RLYB vs Healthcare Sector
How Rallybio Corp compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is RLYB Overvalued or Undervalued?
Based on fundamental analysis, Rallybio Corp has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
RLYB Balance Sheet & Liquidity
RLYB 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Rallybio Corp's revenue has grown significantly by 43% over the 5-year period, indicating strong business expansion. The most recent EPS of $-10.61 indicates the company is currently unprofitable.
RLYB Growth Metrics (YoY)
RLYB Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $212.0K | -$3.1M | $-0.07 |
| Q2 2025 | $212.0K | -$9.7M | $-0.22 |
| Q1 2025 | N/A | -$9.4M | $-0.21 |
| Q3 2024 | N/A | -$11.5M | $-0.26 |
| Q2 2024 | N/A | -$16.2M | $-0.37 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
RLYB Capital Allocation
RLYB SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Rallybio Corp (CIK: 0001739410)
📋 Recent SEC Filings
❓ Frequently Asked Questions about RLYB
What is the AI rating for RLYB?
Rallybio Corp (RLYB) has an AI rating of SELL with 72% confidence, based on fundamental analysis of SEC EDGAR filings.
What are RLYB's key strengths?
Claude: Strong balance sheet with $31.4M cash and zero debt. Excellent liquidity position (14.50x current and quick ratios).
What are the risks of investing in RLYB?
Claude: Severe cash burn of $29.8M annually against minimal $858K revenue creates approximately 1-year runway. Operating losses of $33.1M indicate pre-commercial stage with no clear path to profitability.
What is RLYB's revenue and growth?
Rallybio Corp reported revenue of $858.0K.
Does RLYB pay dividends?
Rallybio Corp does not currently pay dividends.
Where can I find RLYB SEC filings?
Official SEC filings for Rallybio Corp (CIK: 0001739410) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is RLYB's EPS?
Rallybio Corp has a diluted EPS of $-1.59.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is RLYB a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Rallybio Corp has a SELL rating with 72% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is RLYB stock overvalued or undervalued?
Valuation metrics for RLYB: ROE of -15.5% (sector avg: 15%), net margin of -1,046.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy RLYB stock in 2026?
Our dual AI analysis gives Rallybio Corp a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is RLYB's free cash flow?
Rallybio Corp's operating cash flow is $-29.8M, with capital expenditures of $0.0. FCF margin is -3,474.7%.
How does RLYB compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -1,046.4% (avg: 12%), ROE -15.5% (avg: 15%), current ratio 14.50 (avg: 2).